Clinical Effect of Modified Shengyang Yiwei Decoction in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome due to Spleen and Stomach Weakness

Objective:To explore the therapeutic effect of Shengyang Yiwei Decoction in patients with diarrhea-predominant irritable bowel syndrome(IBS)due to spleen and stomach weakness.Methods:40 patients with diarrhea-predominant IBS who were treated from April 2018 to April 2020 were taken as samples.TCM(traditional Chinese medicine)syndrome differentiation found that they were all due to spleen and stomach weakness.They were randomly divided into two groups.Group A was treated with modified prescriptions of Shengyang Yiwei Decoction,while Group B was treated with Western medicine.The therapeutic effects in the two groups were compared.Results:The treatment efficacy in Group A was higher than that in Group B(P<0.05);the symptom scores of Group A such as loose stools,chills,physical weakness,poor appetite,and abdominal distension after meals were all lower than those in Group B(P<0.05);the SF-36(36-Item Short Form Health Survey)scores of patients with diarrhea-predominant IBS in Group A were higher than those in Group B(P<0.05);the treatment satisfaction of Group A was higher than that of Group B(P<0.05).Conclusion:Treatment of diarrhea-predominant IBS patients with spleen and stomach weakness by Shengyang Yiwei Decoction can promote the disappearance of gastrointestinal discomfort symptoms,improve the quality of life,and enhance treatment efficacy.Hence,it is an efficient and feasible treatment for diarrhea-predominant IBS due to spleen and stomach weakness.

Clinical Observation of the Therapeutic Effects of Wenzhong Hewei Formula in Treating Spleen and Stomach Qi Deficiency Syndrome in Internal Medicine Diseases

Objective:To observe the clinical efficacy and safety of Wenzhong Hewei Formula in treating spleen and stomach qi deficiency syndrome in internal medicine diseases.Methods:Sixty patients with spleen and stomach qi deficiency syndrome admitted to the hospital from April 2022 to June 2023 were randomly divided into observation and control groups,with 30 patients in each group.The control group received conventional internal medicine treatment,while the observation group was additionally treated with Wenzhong Hewei Formula on the basis of conventional treatment.Both groups were treated for 4 weeks.Results:The total effective rate of treatment in the observation group was higher than that of the control group(P<0.05).After treatment,the traditional Chinese medicine syndrome scores of both groups were significantly lower than before treatment,with the observation group showing a more pronounced reduction(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Wenzhong Hewei Formula can effectively improve clinical symptoms in patients with spleen and stomach qi deficiency syndrome,enhance clinical efficacy,and have a high level of safety,making it worthy of clinical promotion.

Current concept of Spleen Stomach theory and Spleen deficiency syndrome in TCM

ＣｕｒｅｎｔｃｏｎｃｅｐｔｏｆＳｐｌｅｅｎＳｔｏｍａｃｈｔｈｅｏｒｙａｎｄＳｐｌｅｅｎｄｅｆｉｃｉｅｎｃｙｓｙｎｄｒｏｍｅｉｎＴＣＭＷＵＸｉｅＮｉｎｇＳｕｂｊｅｃｔｈｅａｄｉｎｇｓｓｐｌｅｅｎｄｅｆｉｃｉｅｎｃｙｓｙｎｄｒｏｍｅ；ｓｐｌｅｅｎｓ...

CLINICAL STUDY ON SPLEEN-STOMACH-REINFORCING MOXIBUSTION TREATMENT OF DIARRHEA-TYPE IRRITABLE BOWEL SYNDROME

In the present paper, the therapeutic effect of spleen- stomach- reinforcing moxibustion for treatment of irritable bowel syndrome (IBS) is observed and its underlying mechanisms on immunity are analyzed. A total of 72 IBS patients are randomly divided into moxibustion group (n= 46) and acupuncture group (control group, n = 26). Acu-points used are Zhongwan (CV 12), Qihai (CV 6) and Zusanli (ST 36), etc. Serum IgG, IgA and IgM contents, blood T-lympocytes (T3+, T4+, T8+) counts, T4+ /T8+, cancer embryonic antigen (CEA) content, serum IL-2 and slL-2R contents are assayed for evaluating changes of the immunocompetence. After two courses of treatment (24 sessions), results show that in moxibustion group, 25 cases (54.35%) are cured, 17 experience improvement in clinical symptoms and 4 have no apparent changes, with an effective rate of 91.30% ; in control group, 8 cases (30. 78%) are cured, 12 experience improvement and 6 have no marked improvement, with an effective rate of 76.92% . The therapeutic effect of moxibustion is significantly superior to that of acupuncture (P<0.01). In addition, moxibustion can effectively rectify abnormal immune function and stabilize human's immunity. This research provides a reliable experimental basis for clinical application of 'principal prescription of moxibustion for reinforcing the spleen and stomach'.

The new idea of children with tic syndrome:regulating the five Zang-organs with spleen and stomach system as the center

The pediatric body of pure yang,the liver is often more than enough,the spleen is often insufficient,Yang moving surplus,and Yin essence is insufficient,at the same time,children are the body of immature yin and yang,prone to imbalance of yin and Yang,so deficiency of phlegm accumulation and endogenous liver wind,feel ill at ease,dysfunction of lung qi,Insufficiency of kidney yin are the fundamental pathogenesis of children with tic syndrome.This article discusses the relationship between children with tic syndrome and the five Zang-organs,and how to regulate the viscera through regulating the spleen and stomach system,treating both manifestation and root cause of disease,and put forward a new treatment that the spleen and stomach system should be taken as the center to regulate the five Zang-organs in children with tic syndrome,which should be resolved in order of importance and urgency and treated in stages.

Efficacy of Pidan Jianqing decoction in treatment of type 2 diabetes with spleen deficiency and damp-heat syndrome

Introduction:This study aimed to assess the clinical efficacy of Pidan Jianqing decoction in the treatment of type 2 diabetes.Methods:A total of 72 patients with type 2 diabetes differentiated as spleen deficiency with damp-heat syndrome were randomly assigned to a treatment group(n=35)or control group(n=32).Patients in the control group received diet and exercise guidance and medication in the form of 0.5 g metformin hydrochloride tablets,while patients in the treatment group received Pidan Jianqing decoction in addition to the treatment given to the control group.Efficacy was evaluated after 8 weeks of treatment.Results:Efficacy was 91.4%in the treatment group versus 68.8%in the control group,which was a statistically significant difference(P<0.05).Significant group differences were also noted in the number of patients with improvement in symptoms such as dry mouth and polydipsia,frequency of urination and polyuria,abdominal distention and loss of appetite,fatigue and weakness,and sticky stools(all P<0.05),with greater improvement in the treatment group compared to the control group.The fasting blood glucose(FBG)and 2 h postprandial blood glucose levels significantly improved in both groups after treatment(P<0.05);however,there was no significant difference in glycated hemoglobin levels before and after treatment in both groups.Conclusion:Pidan Jianqing decoction can lower blood glucose levels and improve symptoms in patients with type 2 diabetes.

黄芪建中汤合暖胃汤治疗患儿脾胃虚寒型急性肠胃炎

目的观察黄芪建中汤合暖胃汤治疗脾胃虚寒型急性肠胃炎患儿的疗效。方法选取2021年2月-2023年5月医院收治的74例脾胃虚寒型急性肠胃炎患儿,以随机数字表法分为研究组与对照组,各37例。2组均接受对症治疗,对照组在此基础上采用奥美拉唑肠溶胶囊治疗,研究组在对照组的基础上接受黄芪建中汤合暖胃汤治疗。2组均治疗14 d。对比2组中医证候评分、病症恢复时间、临床疗效、炎症反应、胃肠激素及不良反应。结果治疗后,2组主症评分、次症评分、总评分明显降低(P<0.05),且研究组降低更为明显(P<0.05)。研究组发热、腹痛、呕吐、腹泻等病症恢复时间短于对照组(P<0.05)。研究组总有效率高于对照组(P<0.05)。治疗后,2组白细胞介素-17(IL-17)、基质金属蛋白酶-3(MMP-3)、中性粒细胞与淋巴细胞比值(NLR)水平明显降低(P<0.05),且研究组降低更为明显(P<0.05)。治疗后,2组胃泌素(GSA)水平明显降低(P<0.05),且研究组降低更为明显(P<0.05)。治疗后,2组胃动力素(MTL)水平明显升高(P<0.05),且研究组升高更为明显(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论黄芪建中汤合暖胃汤治疗脾胃虚寒型急性肠胃炎患儿疗效确切,可改善患儿临床症状与胃肠功能,促进患儿康复,减轻炎症反应,且安全可靠。

田耀洲教授辨治慢性萎缩性胃炎经验采撷

慢性萎缩性胃炎(CAG)是消化系统常见病,具有病情反复、缠绵难愈的特点。病理主要以胃腺体的萎缩、伴或不伴有肠上皮化生或异型增生为特征。肠上皮化生和异型增生属于癌前病变,与胃癌的发生关系密切,积极控制CAG患者的临床症状,延缓其病理进展或逆转其病理变化,有利于改善患者的生活质量、减轻经济负担及预防胃癌发生。田耀洲教授认为此病属本虚标实,脾胃虚弱是本,气滞、湿郁、瘀血为标,虚、滞、湿、瘀相互胶结推动着疾病的进展,在辨证上推崇微观与宏观相结合,用药上推崇中西医结合,并擅用经方与药对,精准辨治与用药。田教授开创的自拟方剂芪芝方,疗效显著,可有效改善脾胃湿热型CAG的临床症状。今将田教授辨治CAG之经验及自拟方剂分享给大家,以期为临床辨治CAG提供参考借鉴。

国医大师杨春波辨治脾胃湿热证胃肠病经验

杨春波教授为全国第3届国医大师,擅长运用“脾胃湿热”理论诊治胃肠系统疾患。杨老认为,脾胃湿热由内外因素共同作用而成,应从“三因制宜”角度辨识脾胃湿热证胃肠病的个体化病因病机及临床特征。针对脾胃湿热证胃肠病的辨治用药,杨老以清化湿热、调气舒络为总治则,创制“清化饮”为基本方,并结合辨析寒热、分利三焦、顾护正气、扶正防邪等辨治心得立方。作者结合杨老临床验案,阐述杨老辨治脾胃湿热证胃肠病的临证经验,以期对指导临床诊治有所裨益。

陆氏健脾和胃针刺法治疗代谢综合征的随机对照研究

目的:观察陆氏健脾和胃针刺法治疗代谢综合征(MetS)的临床疗效。方法:选取2020年3月至2022年3月于上海市第七人民医院就诊的MetS患者90例作为研究对象,按照随机数字表法分为观察组和对照组,每组45例。对照组采用健康宣教及常规药物治疗,观察组在此基础上加用陆氏健脾和胃针刺法。比较2组患者治疗前后体质量、腰围、体质量指数(BMI)、血脂、血糖、血压的变化。结果:意向性治疗(ITT)分析结果显示,2组患者各时间点体质量、腰围及BMI均较治疗前显著降低(P<0.05),且观察组各时间点体质量、腰围及BMI显著低于对照组(P<0.05);2组患者治疗后血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)均较治疗前下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)明显上升(P<0.05),治疗后观察组TC、TG、HDL-C变化幅度较对照组更显著(P<0.05);2组患者治疗后空腹血糖(FBG)、糖化血红蛋白(HbA1c)及胰岛素抵抗指数(HOMA-IR)均比治疗前降低(P<0.05),治疗后观察组FPG、HbA1c及HOMA-IR值均比对照组降低明显(P<0.05)。2组患者治疗前后血压指标无明显变化(P>0.05),针刺期待值与临床疗效无明显相关性(P>0.05)。结论:陆氏健脾和胃法针刺法能有效降低MetS患者的体质量、腰围、BMI,改善血脂、血糖水平,并且具有良好的远期疗效。

益胃宁胶囊联合瑞巴派特片治疗慢性萎缩性胃炎脾胃气虚证临床研究

目的观察益胃宁胶囊联合瑞巴派特片治疗慢性萎缩性胃炎(CAG)脾胃气虚证的临床疗效。方法采用随机数字表法将80例CAG患者分为研究组和对照组各40例,2组均予瑞巴派特片,0.1 g/次,每日3次,口服;研究组在此基础上予益胃宁胶囊,2 g/次,每日3次,口服。2组均连续治疗12周。观察2组治疗前后中医疗效、胃镜疗效和病理疗效,比较2组治疗前后中医症状评分,监测2组不良反应。结果2组均无病例脱落。研究组中医疗效总有效率为92.5%(37/40),对照组为70.0%(28/40),研究组中医疗效优于对照组(P<0.01)。与本组治疗前比较,2组治疗后中医症状总分下降(P<0.05,P<0.01);2组治疗后比较,研究组中医症状总分低于对照组(P<0.01)。研究组胃镜疗效总有效率(82.5%)优于对照组(67.5%),研究组病理疗效总有效率(87.5%)优于对照组(70.0%),差异均有统计学意义(P<0.05,P<0.01)。2组未见明显不良反应。结论益胃宁胶囊联合瑞巴派特片可有效改善CAG患者的临床症状、胃镜表现及黏膜病变程度,疗效显著。

泻黄散加味治疗脾胃积热型小儿便秘疗效及对证候积分的影响

目的研究泻黄散加味与排便训练联合治疗脾胃积热型小儿便秘疗效以及对证候积分和复发的影响。方法将2019年7月—2021年7月共101例脾胃积热型便秘患儿纳入研究,采用随机数字表法将患儿分为两组,分别为对照组50例和观察组51例,对照组接受双歧杆菌三联活菌胶囊和排便训练,而观察组采用泻黄散加味颗粒和排便训练治疗。观察治疗后2组患儿用药前后便秘改善程度及临床疗效差异,比较治疗前后2组患儿中医证候积分、胃肠激素水平[血清胃动素(MTL)、胃泌素(GAS)、胃饥饿素(GHR)]、血清学指标水平[血清P物质(SP)、血管活性肠肽(VIP)、一氧化氮(NO)],统计2组不良反应以及半年内复发率并进行比较。结果治疗4周后,2组便秘患者症状自评量表(PAC-SYM)各项评分、大便干结、腹胀、舌红苔黄、口干口臭均较治疗前明显降低(P<0.05),且观察组低于对照组(P<0.05);2组患儿MTL、GAS、GHR、SP、VIP指标均较治疗前显著提升(P<0.05),且观察组比对照组更高(P<0.05),NO显著降低(P<0.05),且观察组比对照组更低(P<0.05)。2组患儿在治疗期间不良反应发生率相似,差异没有统计学意义(P>0.05)。所有患儿治疗2个月均已治愈,经过6个月的随访,观察组便秘复发率明显低于对照组(P<0.05)。结论泻黄散加味与排便训练联合治疗脾胃积热型患儿便秘表现出显著效果,使患儿便秘症状和胃肠激素表达均得到可观改善,纠正其消化系统的神经调节机制,有利于预防复发。

从“内伤脾胃,百病由生”探析糖尿病泌汗异常

《脾胃论》提出了“内伤脾胃,百病由生”的认识,以此为理论基础探讨糖尿病泌汗异常病机演变及辨证治疗。认为本病的发展为饮食劳役,先伤脾胃,导致元气亏损,阴火上行,进而营卫失和,阳损及阴,致汗出异常。治疗上应当注重糖尿病的治疗,兼顾汗证。食疗为先,重用甘味,补阳泻火,平衡气火。明确糖尿病泌汗异常与中焦脾胃功能的密切关系,以期提高临床辨证论治疗效。

四合汤对脾胃虚弱证慢性萎缩性胃炎的影响

目的 探究加味四合汤对脾胃虚弱型慢性萎缩性胃炎的疗效。方法 选取2020年8月—2023年6月河南省永城市人民医院门诊收治的脾胃虚弱证慢性萎缩性胃炎患者120例,根据随机数字表法分为观察组和对照组,每组60例,观察组采用加味四合汤治疗,对照组采用西药治疗,比较2组中医证候积分、胃镜下黏膜表现、组织病理结果的改变。结果 观察组疗效明显优于对照组,差异具有统计学意义(P<0.05)。结论 加味四合汤对脾胃虚弱证慢性萎缩性胃炎患者疗效显著,能有效改善患者临床中医证候、症状、胃镜黏膜表现、组织病理的变化,部分患者黏膜腺体萎缩出现逆转。

消食药在肿瘤治疗中的运用规律

中医认为脏腑气血亏虚、痰瘀毒邪互结是肿瘤发病中的重要因素。消食药健运中焦、疏肝理气、祛痰逐瘀等功效与肿瘤正虚邪实的核心病机高度契合,在肿瘤治疗中发挥着独特作用,现代药理学研究表明此类药物可以通过调节肠道菌群、抑制炎症介质表达、抑制血管生成、诱导细胞凋亡等抗肿瘤。临证时应谨守病机、随证加减、合理配伍、巧妙化裁、注意禁忌。

刘小斌运用麻附细辛汤合甘草干姜汤加减治疗先天性肌无力综合征经验

先天性肌无力综合征(congenital myasthenia syndrome,CMS)为临床罕见的遗传性肌病。CMS患者虽与重症肌无力患者的症状相似,均有肌无力、易疲劳等症,但CMS为先天禀赋不足疾病,以肾元亏损为本,而重症肌无力为后天失养疾病,故在辨治侧重上有所区别。刘小斌教授认为,CMS的中医病机特点为“先天不足,肾元亏损”“脾胃虚损,五脏相关”,属于中医“痿病”范畴;根据患者不易出汗、舌淡红苔白、脉细的病症表现,可辨为脾肾阳虚兼寒邪束表证(少阴太阴兼太阳证);治疗可采用温阳补肾、健脾益损法,常以麻附细辛汤合甘草干姜汤加减,可酌加桑螵蛸、紫河车等益精养血之品,可获显效。

刘启泉从“通调五脏安脾胃”论治尿道综合征经验

总结刘启泉教授从“通调五脏安脾胃”论治尿道综合征的临证经验。刘教授认为,尿道综合征病位在尿道,核心病机为脾胃不和,湿邪阻滞,水道不利,治疗应以“安脾胃”贯穿始终。同时,该病与五脏不调密切相关,外感、内伤、情志、饮食、劳倦及脏腑失调等均会影响五脏功能继而发病。临床中基于“通调五脏安脾胃”思想,根据患者症状表现,综合运用升清降浊以和胃通淋、养心清心以泻热通淋、益肺泻热以利湿通淋、补肾温阳以化气通淋、疏肝清肝以行气通淋的方法指导治疗,可使五脏调和,水道得利,症状缓解,淋证得瘥。

慢性萎缩性胃炎肝胃气滞证和脾胃虚弱证患者血清代谢组学特征研究

【目的】基于非靶向代谢组学技术,分析慢性萎缩性胃炎(chronic atrophic gastritis,CAG)肝胃气滞证和脾胃虚弱证患者的代谢组学特征,发现与CAG患者中医证型相关的血清代谢差异物,为中医辨证客观化提供参考依据。【方法】纳入60例CAG患者,其中肝胃气滞证及脾胃虚弱证各30例。收集2组患者空腹肘静脉血5 mL,采用超高效液相色谱-质谱技术检测血清代谢物含量,采用主成分分析(PCA)、正交偏最小二乘法判别分析(OPLS-DA)和聚类分析等多元统计方法筛选CAG肝胃气滞证和脾胃虚弱证患者之间的差异代谢物,最后利用KEGG数据库对筛选的差异代谢物进行代谢物通路分析。【结果】通过比较CAG肝胃气滞证和脾胃虚弱证患者血清代谢物,发现CAG肝胃气滞证和脾胃虚弱证之间N-乙酰基甘氨酸、组胺、O-磷酸丝氨酸、硒甲基硒代半胱氨酸、甲基间酪氨酸等氨基酸衍生物和酪氨酸-亮氨酸-苯丙氨酸、组氨酸-丙氨酸-谷酰胺-赖氨酸、L-天冬酰胺基-L-脯氨酰-L-丝氨酸、L-异亮氨酸-L-异亮氨酸等小肽类物质代谢具有显著性差异。【结论】CAG肝胃气滞证和脾胃虚弱证患者之间存在氨基酸代谢差异,N-乙酰基甘氨酸、甲基间酪氨酸、O-磷酸丝氨酸等代谢物可能是区别CAG肝胃气滞证和脾胃虚弱证的潜在生物标志物。

连朴泻心汤治疗脾胃湿热型慢性萎缩性胃炎临床研究

目的:观察自拟连朴泻心汤治疗脾胃湿热型慢性萎缩性胃炎的临床疗效。方法:将74例慢性萎缩性胃炎患者按照随机数字表法分为对照组和观察组,每组各37例。对照组予西医常规治疗,观察组在对照组治疗的基础上口服自拟连朴泻心汤。比较两组患者胃镜疗效、幽门螺杆菌(helicobacter pylori, Hp)清除率及治疗前后临床症状评分、临床症状分级情况。结果:对照组有效率为81.08%,观察组有效率为94.59%,两组患者有效率比较,差异具有统计学意义(P<0.05)。两组患者治疗后临床症状积分低于本组治疗前,且观察组低于同期对照组(P<0.05)。对照组Hp阳性12例,转阴3例,清除率为25%;观察组Hp阳性12例,转阴6例,清除率为40%,两组患者Hp清除率比较,差异具有统计学意义(P<0.05)。两组患者治疗后轻度患者例数多于本组治疗前,重度患者少于本组治疗前,且治疗后组间比较,差异具有统计学意义(P<0.05)。结论:自拟连朴泻心汤治疗脾胃湿热型慢性萎缩性胃炎临床疗效确切,可缓解患者胸脘部胀满、胃脘部热痛、口苦、口黏、头身重着、纳呆嘈杂等不适症状,并能修复损伤的胃黏膜。

刘凤斌对慢性萎缩性胃炎“炎-癌”转化的病机探索与辨治思路

慢性萎缩性胃炎(chronic atrophic gastritis,CAG)是临床上常见的难治性胃病,属于胃癌前病变。刘凤斌教授及其团队历经30余年的探索和实践,提出“脾虚为本,气血湿为标,瘀毒为变”是CAG“炎-癌”转化的病机演变特点。脾胃虚弱为CAG发病的始动因素,贯穿疾病始终;气滞、血瘀、湿阻为CAG“炎-癌”转化的触发和加重因素;瘀毒的形成是CAG进展和转变的关键。辨治应遵循“证镜结合,分期论治”的原则,辨病和辨证相结合,宏观和微观辨证相补充;健脾扶正需贯穿始终。CAG早期阶段(胃黏膜以轻中度萎缩伴或不伴轻度肠上皮化生),其病机以脾胃虚弱为本,伴有气滞、湿阻、血瘀病理因素,治疗以健脾清热、理气活血为基本治法;CAG晚期阶段(胃黏膜重度萎缩伴或不伴中重度肠上皮和/或轻中度上皮内瘤变),基本病机为脾胃虚弱、痰瘀互结、胃络瘀毒,治疗以扶正散结、通络解毒为基本治法,从而构筑中医药阻断胃“炎-癌”转化的整体防线。